AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central America. AMW’s goserelin implant is the only approved generic implant version to date for AstraZeneca’s originator product Zoladex®1. Goserelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate or breast cancer, as well as certain gynecological diseases. AMW’s goserelin implant is now available to patients in approximately 30 countries worldwide as a cost-effective alternative therapy.
AMW develops and produces innovative, bio-degradable sustained-release drug delivery systems, such as the GnRH analogue implants goserelin and leuprorelin. For global commercialization, the products are licensed to international and regional partners. AMW is the exclusive manufacturer and provider of these implants and also receives royalties on licenses from its partners. To date, goserelin has been licensed to leading global and local pharmaceutical enterprises in more than 50 countries. In Germany, AMW’s products are distributed by the Company’s wholly owned subsidiary Endomedica GmbH.
“We are excited that, together with our distribution partners, we are now able to offer goserelin to a much higher number of patients in Europe and Central America,” commented Dr. Konstantin Petropoulos, CEO of AMW. “Access to generics or value added medicines of this drug class is still very limited, particularly in Europe. Together with our partners, we remain committed to making all our products widely available as improved and cost-effective alternative therapies. As a market leader for biodegradable sustained-release products, we expect further approvals of our products within the EU and beyond in the current year.”
AMW GmbH is a specialty pharmaceutical company focused on innovative bio-degradable sustained-release drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology. AMW currently has four marketed products (goserelin & leuprorelin implants, rivastigmine & buprenorphine patches).
AMW is based in Warngau, south of Munich, Germany.
Goserelin implant contains the active ingredient goserelin and belongs to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormonesensitive tumors such as prostate cancer or breast cancer with goserelin. In addition, goserelin is used to treat certain benign gynecological disorders. Goserelin is administered in the form of a biodegradable implant which releases the active ingredient over a period of either one or three months.
For more information please contact:
Dr. Konstantin Petropoulos
Phone: +49 8024 470999-0
1Zoladex® is a registered trademark of Astra Zeneca UK Limited.